Physician profile
Nay Linn Aung
NPI 1972911352
$12,133.05
in general payments reported to CMS, 2019-2025
14 companies · $12K in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $138 · 2021: $87.60 · 2022: $22.07 · 2023: $74.29 · 2024: $17.49 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,881 · Travel and Lodging: $1,030 · Food and Beverage: $734 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,881.25 |
| Travel and Lodging | $1,030.09 |
| Food and Beverage | $733.77 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $11,657.21 | 2021-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $84.31 | 2019-2023 | Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $66.79 | 2020-2023 | Farxiga |
| Lilly USA, LLC | $50.90 | 2023-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $45.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $34.56 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.70 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $31.78 | 2019 | |
| Pfizer INC. | $30.16 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $25.25 | 2019 | |
| Beta Bionics, INC. | $25.00 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Vapotherm INC | $18.01 | 2021 | |
| Sequel Med Tech, LLC | $15.57 | 2025 | Twiist |
| E.R. Squibb & Sons, L.L.C. | $15.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nay Aung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.